Evidence map›Paper›PMID 26502369›Full record

ArticleTransplantation2016

Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts.

Ágnes Prókai, Rózsa Csohány, Erna Sziksz, Domonkos Pap, Leonóra Balicza-Himer, Szilvia Boros, Balázs Magda, Ádám Vannay, Katalin Kis-Petik, Andrea Fekete and 2 more

Open access · greenAbstract read
In one paragraph

Article in Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?Advances in chronic kidney disease · 2020
    Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Ágnes Prókai *First Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Rózsa Csohány *First Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Erna SzikszFirst Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Domonkos PapFirst Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Leonóra Balicza-HimerFirst Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Szilvia BorosFirst Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Balázs MagdaInstitute of Organic Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
Ádám VannayFirst Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Katalin Kis-PetikDepartment of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.
Andrea FeketeFirst Department of Pediatrics, Semmelweis University, Budapest, Hungary.
János Peti-PeterdiDepartment of Physiology and Biophysics, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, CA.
Attila J SzabóFirst Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Semmelweis University · HUHUN-REN Research Centre for Natural Sciences · HUUniversity of Southern California · US

Funding

Multiphoton Imaging of the Juxtaglomerular ApparatusR01DK064324 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JANOS PETI-PETERDI · 2004 to 2026
$8.4M
Novel imaging approach to study podocyte function in vivoR01DK100944 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PETI-PETERDI, JANOS · 2014 to 2017
$1.5M
NIDDK NIH HHS R01 DK064324NIDDK NIH HHS R01 DK100944
6 · The paper itself

Abstract

backgroundTacrolimus (Tac) and Cyclosporine A (CyA) calcineurin inhibitors (CNIs) are 2 effective immunosuppressants which are essential to prevent allograft rejection. Calcineurin inhibitors are known to be nephrotoxic. However, the precise mechanism of nephrotoxicity is not fully understood. In this study, we investigated the in vivo effects of CNIs on the local renal renin-angiotensin system in the collecting duct (CD).

methodsThree-week-old mice were treated with either vehicle, CyA (2 mg/kg per day), Tac (0.075 mg/kg per day), CyA + Aliskiren (25 mg/kg per day), or Tac + Aliskiren for 3 weeks. Serum creatinine was measured. Renin and vascular endothelial growth factor (VEGF) contents in CD were evaluated with flow cytometry and multiphoton microscopy. The diameter of vessels was assessed with multiphoton microscopy, and the amount of renal collagen was determined by real-time polymerase chain reaction and Masson staining.

resultsThe elevated level of serum creatinine in CNI groups was abolished by Aliskiren. Flow cytometric analysis found elevated renin content in principal cells, which was prevented by Aliskiren. This result was further confirmed with multiphoton microscopy. The VEGF content in CD correlated with reduced capillary diameter and with the formation of fibrotic islands.

conclusionsCalcineurin inhibitors induce production of renin in the CD that may contribute to decreased renal blood flow. In turn, CD responds with increased VEGF production, resulting in disproportional vessel growth, further worsening the local hypoxia and striped fibrosis surrounding the CDs. Aliskiren, a direct renin inhibitor blocks these effects and improves CNI-induced nephropathy by decreasing renin production in the CDs. Our data suggest that Aliskiren may be used for the prevention of CNI nephrotoxicity.

Indexed as

Calcineurin InhibitorsCyclosporineImmunosuppressive AgentsTacrolimusAmidesAnimalsBiomarkersCapillariesCollagen Type ICreatinineCytoprotectionDisease Models, AnimalFibrosisFlow CytometryFumaratesKidney DiseasesaliskirenAmidesBiomarkersCalcineurin InhibitorsCollagen Type ICreatinineCyclosporineFumaratesImmunosuppressive AgentsReninRenin InhibitorsTacrolimusVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Identifiers

PMID26502369
PMCPMC4870017
OpenAlexW2329728034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.